Placental Growth Factor (PlGF) based testing for pre-eclampsia

Pre-eclampsia (PE) affects approximately three per cent of all pregnancies and is a serious cause of maternal and foetal morbidity. There is no definitive test to help diagnose PE and the only “cure” is delivery of the baby. High suspicion for the disease and a low threshold for admission places a considerable unnecessary burden on the system, something that PlGF based testing aims to alleviate.

Project overview

PlGF based testing provides fast and accurate diagnosis if PE is suspected, using a simple blood test for placental biomarkers. Blood tests available from Roche Diagnostics (Roche Elecsys sFlt-1/PlGF Ratio Test) and Quidel Corporation (Quidel Triage PlGF test) help to identify which women;
• do not have pre-eclampsia;
• have or are at risk of developing pre-eclampsia;
• or are at risk of pre-term delivery.

The product is recommended by NICE between 20 weeks and 34 weeks plus six days of gestation. The improved diagnosis allows better ante-natal risk management and provision of appropriate care according to clinical need, with subsequent financial and capacity benefits for the maternity system.

The Health Innovation Network (HIN) is currently working with stakeholders including suppliers and clinicians to support with the implementation and adoption of PlGF based testing in south London. It is currently being used in St Thomas’, Kingston, St George’s and Lewisham and Greenwich Trusts. The NICE approved product is available through the Rapid Uptake Products (RUP) programme, the 2020/21 Innovation and Technology payment (ITP) programme and is also expected to be a MedTech Funding Mandate (MTFM) pilot product from April 2021.

We're here to help

Please get in touch for further information regarding the clinical, financial and patient benefits of PlGF based testing and for details regarding adopting the product in your organisation via the MTFM.

Email the team
 

By Rita Mogaiji

Share: